111 Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
111 Capital's ALNY Position: Q3 2026 in Review
111 Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 36% in Q3 2026, selling an estimated $223K and leaving 1,534 shares worth $378K. The position accounts for 0.06% of the portfolio, ranked #370.
111 Capital first reported a position in ALNY in Q4 2025 and has held it in 4 quarters since. The position peaked at $726K in Q2 2026. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- 111 Capital held 1,534 shares of Alnylam Pharmaceuticals worth $378K as of Q3 2026.
- 111 Capital sold 878 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $223K.
- Alnylam Pharmaceuticals made up 0.06% of 111 Capital's portfolio in Q3 2026, its #370 holding.
- 111 Capital first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- 111 Capital's Alnylam Pharmaceuticals position peaked at $726K in Q2 2026.
- 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on 111 Capital's 13F filing for Q3 2026, filed 3 Nov 2026.